...Eurofins began a tender offer to acquire Cerep for €2 per share, or about €25.3 million...
...deal was announced. Cerep's board unanimously approved the deal. The tender offer expires Feb. 27. Cerep...
...services for in vitro pharmacology, in vitro ADMET and in vivo pharmacokinetics for drug development. Cerep...

...stabilizer in Phase III testing for Huntington's disease; expects to save $17.3M by 2012 1/18/11 Cerep...

...company will close its office in Paris, France, and move its headquarters to Celle L'Evescault. Cerep...
...pharmacology, in vitro ADMET and in vivo pharmacokinetics for drug development. At June 30, 2010, Cerep...
...of €11.2 million ($13.7 million) and a six-month operating loss of €1.4 million ($1.7 million). Cerep...

...to pay the interest on debt owed to Cerep stemming from Averion's 2007 acquisition of Cerep's...
...the debt are ongoing (see BioCentury, Nov. 5, 2007). Averion International Corp. (OTCBB:AVRO), Southborough, Mass. Cerep...

...not disclosed. Separately, Cerep will screen Servier's compound library against targets identified by the pharma. Cerep...
...will be responsible for development and validation of pharmacological assays and profiling the compounds identified. Cerep...
...will receive an undisclosed monthly payment during the three-year deal. Further terms were not disclosed. Cerep...

...exclusive, worldwide license to develop and commercialize Cerep's LFA-1 (CD11a-CD18) antagonist to treat ophthalmic disorders. Cerep...
...in animal models, which is expected to begin this half. The compound was discovered under Cerep's...
...to Cerep after hepatotoxicity was observed during Phase II testing for autoimmune and inflammatory diseases. Cerep...

...Inc. (NASDAQ:BIIB), Cambridge, Mass. BioInvent International AB (SSE:BINV), Lund, Sweden Biovitrum AB (SSE:BVT), Stockholm, Sweden Cerep...
...Corp. and Sunesis Pharmaceuticals Inc. , which have SAR1118 in Phase I testing for conjunctivitis. Cerep...

...payment to Cerep and reimbursement of certain Cerep's expenses. Cerep also is eligible for royalties. Cerep...

...€199.3 Amsterdam Molecular (Euronext:AMT) €102.1 Bioalliance (Euronext:BIO) €88.1 Biotech (Pricaf) (Euronext:BIOT) €19.3 Cellectis (Euronext:ALCLS) €66.0 Cerep...

...Sepal Pharma , Paris, France Business: Cancer Appointed: Frederic Revah as CEO, former CSO of Cerep...